Actively Recruiting
Study of ST266 Given by IV to Assess Safety and Early Effectiveness in Infants with Necrotizing Enterocolitis
Led by Noveome Biotherapeutics, formerly Stemnion · Updated on 2026-04-13
36
Participants Needed
8
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of ST266 in infants with necrotizing enterocolitis NEC at Bells stage IIA or higher. This Phase 1-2 randomized, controlled, open-label trial focuses on infants with NEC weighing between 500g and 3000g. The study aims to assess adverse events and serious adverse events related to the treatment, alongside early signs of efficacy. The study involves four cohorts based on dose levels 0.5 mLkg and 1.0 mLkg and weight ranges 500-999g and 1000-3000g. Participants are randomly assigned to receive either ST266 plus standard of care SOC or SOC alone. Treatment is given once daily intravenously for 10 days, followed by a 28-day follow-up. The Data Safety Monitoring Board reviews safety data before advancing dosing in subsequent cohorts. During the trial, infants will undergo monitoring for adverse events, laboratory tests, and vital signs up to 24 months of age. Researchers will also evaluate clinical measures such as time to resolution of pneumatosis, time to full enteral feeding, need for abdominal surgery, and changes in organ failure scores during treatment. Participation includes regular assessments and monitoring to ensure safety and gather efficacy data over the follow-up period.
CONDITIONS
Brief Title
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Research Team
K
Karin Potoka, MD
S
Shawna M Rose, BS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here